/* mobile /* end mobile MEDDESKTOP: Losartan May Be An Effective Treatment Option For Marfan Syndrome

Wednesday, November 19, 2014

Losartan May Be An Effective Treatment Option For Marfan Syndrome

This randomized trial, which was conducted by the NHLBI’s Pediatric Heart Network, ran from 2007-2011 at 21 clinical centers in the United States, Canada and Belgium and included 608 patients aged 6 months to 25 years.  The two drugs work in different ways. Atenolol works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure. Losartan also known as Cozaar, blocks the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently.
The results of the Atenolol versus Losartan in Children and Young Adults with Marfan Syndrome study, supported by NIH’s National Heart, Lung, and Blood Institute (NHLBI), were presented today at the American Heart Association (AHA) Scientific Sessions in Chicago. The study was published simultaneously in the New England Journal of Medicine.

NIH Release

No comments:

LinkWithin

Related Posts Widget for Blogs by LinkWithin